Rheumatic Immune-Related Adverse Events, An Issue of Rheumatic Disease Clinics of North America
- 1st Edition, Volume 50-2 - May 21, 2025
- Editors: Alexa Simon Meara, David Liew
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 9 4 0 0 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 9 4 0 1 - 3
In this issue of Rheumatic Disease Clinics, guest editors Drs. Alexa Simon Meara and David Liew bring their considerable expertise to the topic of Rheumatic Immune-Re… Read more
Purchase options
In this issue of Rheumatic Disease Clinics, guest editors Drs. Alexa Simon Meara and David Liew bring their considerable expertise to the topic of Rheumatic Immune-Related Adverse Events. Immune checkpoint inhibitors sometimes cause rheumatic-disease-like symptoms, or rheumatic immune-related adverse events (irAEs). In this issue, top experts discuss the utility of laboratory investigations for rheumatic irAEs; the future of biomarkers in rheumatic irAEs; integrating rheumatic irAE research and care into an oncological milieu; patient voices in rheumatic irAE care and research; polymyalgia rheumatica irAEs; inflammatory arthritis irAEs: current approaches to management; and more.
- Contains 15 relevant, practice-oriented topics including myositis irAEs; sicca symptom irAEs; de novo connective tissue disorders as irAEs; imaging in rheumatic irAEs; combining biologic DMARDs with immune checkpoint inhibitors; the impact of DMARDs and glucocorticoids on cancer response to immune checkpoint inhibitors; and more
- Provides in-depth clinical reviews on rheumatic immune-related adverse events, offering actionable insights for clinical practice
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews
Rheumatology
Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression
Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events
The Current and Future of Biomarkers of Immune Related Adverse Events
Immunotherapy Toxicity Management in Clinical Practice: Building the Clinical Infrastructure for Immune-related Adverse Event Evaluation and Care
Patient Voices in Rheumatic Immune-related Adverse Events
Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica
Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management
Immune Checkpoint Inhibitor-induced Myositis
Immune Checkpoint Inhibitor-induced Sicca Syndrome
De novo Connective Tissue Disorders as Immune-related Adverse Events
Imaging in Rheumatic Immune-related Adverse Events
The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review
Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease[1]Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy
Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events
The Current and Future of Biomarkers of Immune Related Adverse Events
Immunotherapy Toxicity Management in Clinical Practice: Building the Clinical Infrastructure for Immune-related Adverse Event Evaluation and Care
Patient Voices in Rheumatic Immune-related Adverse Events
Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica
Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management
Immune Checkpoint Inhibitor-induced Myositis
Immune Checkpoint Inhibitor-induced Sicca Syndrome
De novo Connective Tissue Disorders as Immune-related Adverse Events
Imaging in Rheumatic Immune-related Adverse Events
The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review
Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease[1]Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy
- Edition: 1
- Volume: 50-2
- Published: May 21, 2025
- Language: English
AM
Alexa Simon Meara
Affiliations and expertise
Associate Professor, Division of Oncology, Division Rheumatology and Immunology, The Ohio State Wexner Medical Center, USADL
David Liew
Affiliations and expertise
Consultant Rheumatologist and Clinical Pharmacologist Project Lead, Medicines Optimisation Service, Department of Clinical Pharmacology and Therapeutics, Austin Hospital, Heidelberg, VIC, Australia